{
    "clinical_study": {
        "@rank": "164727", 
        "arm_group": [
            {
                "arm_group_label": "Treatment I", 
                "arm_group_type": "Experimental", 
                "description": "1 tablet of DLBS1033 490 mg thrice daily, after meal"
            }, 
            {
                "arm_group_label": "Treatment II", 
                "arm_group_type": "Active Comparator", 
                "description": "1 tablet of aspirin 80 mg once daily, after meal"
            }, 
            {
                "arm_group_label": "Treatment III", 
                "arm_group_type": "Active Comparator", 
                "description": "1 tablet of clopidogrel 75 mg once daily, after meal"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 3-arm, prospective, randomized, double-blind, and controlled clinical study, with\n      3 months of treatment to evaluate efficacy of DLBS1033 in bleeding profile and clinical\n      outcome in patients with acute ischemic stroke compared with aspirin and clopidogrel, as\n      active controls."
        }, 
        "brief_title": "Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Acute Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "There will be 3 groups of treatment; each group will consist of 43 subjects with the\n      treatment regimens :\n\n        -  Treatment I : 1 tablet of DLBS1033 490 mg thrice daily, after meal\n\n        -  Treatment II : 1 tablet of aspirin 80 mg once daily, after meal\n\n        -  Treatment III : 1 tablet of clopidogrel 75 mg once daily, after meal\n\n      Bleeding profile (by measuring INR value, PT, and aPTT) and clinical outcome (by measuring\n      Gadjah Mada Stroke Scale and Barthel Index) to evaluate the efficacy of the investigational\n      drug will be performed at baseline and end of study (Month 3rd). General condition of the\n      subjects will be followed-up every month over three months of study medication.\n\n      Physiotherapy will be provided to the subjects by the assigned Physiotherapist."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects aged 20-80 years old\n\n          -  Having non-bleeding stroke in CT scan examination\n\n          -  Having stroke attack onset \u2264 96 hours\n\n          -  Living in 100 km from RSUP Dr Sardjito Jogjakarta\n\n        Exclusion Criteria:\n\n          -  Having recurrence stroke\n\n          -  Having Transient Ischemic Attack (TIA)\n\n          -  Have been regularly taking anti-aggregation agent\n\n          -  Having intracerebral and subarachnoid bleeding stroke\n\n          -  Subjects and their family do not know when the stroke symptoms appeared\n\n          -  History of haemostasis disorder\n\n          -  History of or will have surgery within 6 months prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790997", 
            "org_study_id": "DLBS1033-UST-001.11"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment I", 
                "description": "1 tablet of DLBS1033 490 mg thrice daily, after meal", 
                "intervention_name": "DLBS1033", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment II", 
                "description": "1 tablet of aspirin 80 mg once daily, after meal", 
                "intervention_name": "Aspirin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment III", 
                "description": "1 tablet of clopidogrel 75 mg once daily, after meal", 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Ticlopidine", 
                "Clopidogrel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "DLBS1033", 
            "Lumbrokinase", 
            "Acute ischemic stroke", 
            "Bleeding profile", 
            "Clinical outcome", 
            "Aspirin", 
            "Clopidogrel"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Yogyakarta", 
                    "country": "Indonesia", 
                    "state": "Jogjakarta", 
                    "zip": "55281"
                }, 
                "name": "Stroke Unit, Department of Neurology, Faculty of Medicine, Gadjah Mada University, dr. Sardjito Hospital"
            }
        }, 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Role of DLBS1033 in Evaluating Bleeding Profile and Clinical Outcome in Patients With Acute Ischemic Stroke: Comparison With Aspirin and Clopidogrel", 
        "overall_official": {
            "affiliation": "Stroke Unit, Department of Neurology, Faculty of Medicine, Gadjah Mada University, dr. Sardjito Hospital, Jogjakarta, Indonesia", 
            "last_name": "Ismail Setyopranoto, dr., SpS(K)", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change in INR (international normalized ratio) value from baseline to end of study (Month 3rd)", 
            "measure": "Change in INR value", 
            "safety_issue": "No", 
            "time_frame": "3 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790997"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in PT (prothrombin time) from baseline to end of study (Month 3rd)", 
                "measure": "Change in PT", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "description": "Change in aPTT (activated-partial thromboplastin time) from baseline to end of study (Month 3rd)", 
                "measure": "Change in aPTT", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "description": "Change in Gadjah Mada Stroke Scale from baseline to end of study (Month 3rd)", 
                "measure": "Change in Gadjah Mada Stroke Scale", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "description": "Change in Barthel Index from baseline to end of study (Month 3rd)", 
                "measure": "Change in Barthel Index", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }
        ], 
        "source": "Dexa Medica Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dexa Medica Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}